A novel role of Cx43-composed GJIC in PDT phototoxicity: an implication of Cx43 for the enhancement of PDT efficacy

Wu, Dalin; Bai, Li-Ru; Lv, Yan-Fang; Zhou, Yan; Ding, Chun-Hui; Yang, Si-Man; Zhang, Fan; Huang, Jinlan

doi:10.7150/ijbs.29582

Cited by 10 publications

(6 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The need for synergistic agents has also resulted in the development of novel technologies and the identification of targets for gene therapy. Recent reports show that the delivery of micelles with peptide irDG-conjugated photosensitizers results in greater BBB penetration and that upregulation of Cx43, affiliated with poor GBM prognosis [244], improves the efficacy of PDT [168,245].…”

Section: Pdt Drug Interactions and Synergistic Agentsmentioning

confidence: 99%

Systematic Review of Photodynamic Therapy in Gliomas

Hsia

Small

Yekula

et al. 2023

Cancers

View full text Add to dashboard Cite

Over the last 20 years, gliomas have made up over 89% of malignant CNS tumor cases in the American population (NIH SEER). Within this, glioblastoma is the most common subtype, comprising 57% of all glioma cases. Being highly aggressive, this deadly disease is known for its high genetic and phenotypic heterogeneity, rendering a complicated disease course. The current standard of care consists of maximally safe tumor resection concurrent with chemoradiotherapy. However, despite advances in technology and therapeutic modalities, rates of disease recurrence are still high and survivability remains low. Given the delicate nature of the tumor location, remaining margins following resection often initiate disease recurrence. Photodynamic therapy (PDT) is a therapeutic modality that, following the administration of a non-toxic photosensitizer, induces tumor-specific anti-cancer effects after localized, wavelength-specific illumination. Its effect against malignant glioma has been studied extensively over the last 30 years, in pre-clinical and clinical trials. Here, we provide a comprehensive review of the three generations of photosensitizers alongside their mechanisms of action, limitations, and future directions.

show abstract

Section: Pdt Drug Interactions and Synergistic Agentsmentioning

confidence: 99%

Systematic Review of Photodynamic Therapy in Gliomas

Hsia

Small

Yekula

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

“…Because of the advantages such as easy manipulation and rapid amplification, NCI-60 is still widely used in global laboratories, especially for the fundamental research laboratory [ 38 , 39 ]. While the repeatability has been approved in vivo, conclusions based on NCI-60 could not readily translate to the human body [ 7 ].…”

Section: Applicationmentioning

confidence: 99%

Opportunities and challenges of patient-derived models in cancer research: patient-derived xenografts, patient-derived organoid and patient-derived cells

Hou

et al. 2022

World J Surg Onc

View full text Add to dashboard Cite

Background As reported, preclinical animal models differ greatly from the human body. The evaluation model may be the colossal obstacle for scientific research and anticancer drug development. Therefore, it is essential to propose efficient evaluation systems similar to clinical practice for cancer research. Main body While it has emerged for decades, the development of patient-derived xenografts, patient-derived organoid and patient-derived cell used to be limited. As the requirements for anticancer drug evaluation increases, patient-derived models developed rapidly recently, which is widely applied in basic research, drug development, and clinical application and achieved remarkable progress. However, there still lack systematic comparison and summarize reports for patient-derived models. In the current review, the development, applications, strengths, and challenges of patient-derived models in cancer research were characterized. Conclusion Patient-derived models are an indispensable approach for cancer research and human health.

show abstract

“…Також відомо, що щільні міжклітинні з'єднання (GJIC), утворені конексином (Сх) 43, можуть поліпшувати передачу «сигналу смерті» між клітинами, підвищуючи цитотоксичну дію хіміотерапевтичних засобів, генної терапії та ФДТ [73]. Фотодинамічна терапія була ефек тивнішою в к літинах HeL a, трансфікованих Cx43, та клітинах гліоми U87, що експресували Cx43, за умов високої к літинної щільності.…”

Section: експериментальні підходи до підвищення ефективності фотодина...unclassified

“…Крім того, за наявності Cx43-GJIC фотофрин-ФДТ зменшувала масу пухлинних ксенотрансплантатів in vivo. Підвищена ефективність ФДТ, пов'язана із Cx43-GJIC, корелювала із сигнальними шляхами стресу, опосередкованого ROS, Ca 2+ і перекисним окисненням ліпідів [73]. Отже, стратегії підсилення експресії Cx43 або функції Cx43-GJIC можуть підвищити чутливість клітин пухлин до ФДТ та ефективність лікування.…”

Section: експериментальні підходи до підвищення ефективності фотодина...unclassified

Photodynamic therapy of malignant brain gliomas

Rozumenko¹,

Любич²,

Стайно³

et al. 2022

Ukr Neurosurg J

View full text Add to dashboard Cite

Treatment of malignant gliomas of the brain remains a serious problem on a global scale, despite intensive research into the causes and mechanisms of their progression. When using traditional surgical approaches and imaging methods tumor cell infiltrates may be overlooked, as a result of which, malignant gliomas relapse often occurs near the marginal region of the surgical cavity. A method that allows visual identification of tumor tissue and at the same time provides an opportunity to selectively destroy it is photodynamic therapy (PDT) ‒ a two-stage treatment that includes the introduction (intravenous, intraperitoneal, local or oral) of a light-sensitive chemical agent (photosensitizer (PS)) followed by its activation at a certain wavelength of light.The principle of PDT is based on the cytotoxic effects caused by PS, which selectively accumulates in malignant tumor cells and is activated by light rays of the appropriate wavelength, generating singlet oxygen and free radicals, which trigger photochemical reactions in tumor cells with subsequent destruction of protein structures. Tumor tissue has a higher affinity for PSs. PSs are divided into 1st, 2nd and 3rd generation molecules. So far, 3rd generation PSs have not yet been approved for clinical use. In vitro and in vivo experimental studies confirmed the effectiveness of PDT of brain tumors using 2nd generation PSs.The simultaneous use of surgery under the control of fluorescence and PDT enables both the visualization of tumor cells and their selective destruction. Regardless of PDT, PSs are used for the purpose of auxiliary delineation of tumor borders for maximum tumor removal during fluorescence-guided surgery.The review examines the development of PDT in a historical aspect, the contribution of domestic scientists, in particular, scientists of the Institute of Neurosurgery named after acad. A. P. Romodanov, National Academy of Medical Sciences of Ukraine to the development of the problem of PDT in neuro-oncology; preclinical studies of PDT and experimental approaches to increase the efficiency of PDT are characterized. Analysis of data from clinical trials confirms that using PDT as an adjunctive treatment of malignant gliomas administered immediately after maximal resection is safe, reduces the risk of recurrence by targeting residual tumor cells in the resection cavity, improves survival and quality of life of patients. The absence of information on the development of resistance to multiple PDT sessions suggests the possibility of repeated treatments of tumor cells not removed during surgery.

show abstract

A novel role of Cx43-composed GJIC in PDT phototoxicity: an implication of Cx43 for the enhancement of PDT efficacy

Cited by 10 publications

References 33 publications

Systematic Review of Photodynamic Therapy in Gliomas

Systematic Review of Photodynamic Therapy in Gliomas

Opportunities and challenges of patient-derived models in cancer research: patient-derived xenografts, patient-derived organoid and patient-derived cells

Photodynamic therapy of malignant brain gliomas

Contact Info

Product

Resources

About